Put companies on watchlist
SARTORIUS AG
ISIN: DE0007165631
WKN: 716563
Curious about what AI knows about Sartorius? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

SARTORIUS AG · ISIN: DE0007165631 · EQS - Company News (13 News)
Country: Germany · Primary market: Germany · EQS NID: 2127076
02 May 2025 09:22AM

Sartorius Supervisory Board extends appointment of board member Alexandra Gatzemeyer


EQS-News: SARTORIUS AG / Key word(s): Personnel
Sartorius Supervisory Board extends appointment of board member Alexandra Gatzemeyer (news with additional features)

02.05.2025 / 09:22 CET/CEST
The issuer is solely responsible for the content of this announcement.


At today’s meeting, the Supervisory Board of Sartorius AG resolved to extend the appointment of Dr.  Alexandra Gatzemeyer as a member of the Executive Board by a five-year period to April 30, 2031. Gatzemeyer, who holds a Ph.D. in chemistry and pharmacology, has been with Sartorius since 2004 and was appointed to the Executive Board in March 2023. As a board member, she is responsible for the Lab Products & Services Division.


A profile of Sartorius
Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. More than 13,500 employees work for customers around the globe.

Visit our Newsroom or follow us on LinkedIn.


Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 551 308 1686
petra.kirchhoff@sartorius.com

 

Additional features:

File: Image_Alexandra Gatzemeyer_Sartorius
File: 20250502_Media Release_SAG_Extension of appointment of Alexandra Gatzemeyer_EN


02.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2127076

 
End of News EQS News Service

2127076  02.05.2025 CET/CEST

Visual performance / price development - SARTORIUS AG
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.